Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
423 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02631876 | A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer(FORWARD I) | completed | Phase 3 | 366 | ImmunoGen, Inc.INDUSTRY | 13 | Oct 14, 2020 | clinicaltrials |
| NCT00625898 | BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab(BETH) | terminated | Phase 3 | 3,509 | NSABP Foundation Inc |
| 40 |
| Sep 10, 2020 |
| clinicaltrials |
| NCT03745222 | A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer(RATIONALE001) | terminated | Phase 3 | 1 | CelgeneINDUSTRY | 23 | Jul 15, 2020 | clinicaltrials |
| NCT02718417 | Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100) | terminated | Phase 3 | 998 | PfizerINDUSTRY | 25 | Jul 14, 2020 | clinicaltrials |
| NCT01450761 | Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone | completed | Phase 3 | 1,351 | Bristol-Myers SquibbINDUSTRY | 34 | Jul 8, 2020 | clinicaltrials |
| NCT01285609 | Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin | completed | Phase 3 | 1,289 | Bristol-Myers SquibbINDUSTRY | 36 | Jun 18, 2020 | clinicaltrials |
| NCT00418457 | Regional Anesthesia and Breast Cancer Recurrence | completed | Phase 3 | 2,108 | The Cleveland ClinicOTHER | 6 | Jun 16, 2020 | clinicaltrials |
| NCT00003855 | Lymph Node Removal in Treating Women Who Have Stage I or Stage IIA Breast Cancer | completed | Phase 3 | 605 | Alliance for Clinical Trials in OncologyOTHER | 4 | Apr 29, 2020 | clinicaltrials |
| NCT01829711 | Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia | completed | Phase 3 | 80 | MedImmune LLCINDUSTRY | 14 | Apr 8, 2020 | clinicaltrials |
| NCT01569295 | Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela )(Tugela) | completed | Phase 3 | 416 | Gilead SciencesINDUSTRY | 18 | Mar 10, 2020 | clinicaltrials |
| NCT00069121 | A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer | completed | Phase 3 | 1,886 | Hoffmann-La RocheINDUSTRY | 29 | Mar 6, 2020 | clinicaltrials |
| NCT01578707 | A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia(RESONATE™) | completed | Phase 3 | 391 | Pharmacyclics LLC.INDUSTRY | 10 | Dec 18, 2019 | clinicaltrials |
| NCT00689936 | Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma(FIRST) | completed | Phase 3 | 1,623 | CelgeneINDUSTRY | 19 | Nov 20, 2019 | clinicaltrials |
| NCT01905943 | A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia | completed | Phase 3 | 979 | Hoffmann-La RocheINDUSTRY | 31 | Oct 28, 2019 | clinicaltrials |
| NCT01098266 | NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed | completed | Phase 3 | 400 | AGC Biologics S.p.A.INDUSTRY | 12 | Sep 17, 2019 | clinicaltrials |
| NCT01659021 | Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia | terminated | Phase 3 | 261 | Gilead SciencesINDUSTRY | 11 | Aug 14, 2019 | clinicaltrials |
| NCT01667419 | A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma(BRIM8) | completed | Phase 3 | 498 | Hoffmann-La RocheINDUSTRY | 29 | Jul 23, 2019 | clinicaltrials |
| NCT01125566 | LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment | completed | Phase 3 | 508 | Boehringer IngelheimINDUSTRY | 38 | Jul 18, 2019 | clinicaltrials |
| NCT00748189 | Ofatumumab + Chlorambucil vs Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia(COMPLEMENT 1) | terminated | Phase 3 | 447 | Novartis PharmaceuticalsINDUSTRY | 17 | Jun 25, 2019 | clinicaltrials |
| NCT01961609 | Secukinumab in Tumor Necrosis Factor (TNF) - Inadequate Response (IR) Psoriasis Participants.(SIGNATURE) | completed | Phase 3 | 235 | Novartis PharmaceuticalsINDUSTRY | 2 | Mar 18, 2019 | clinicaltrials |
| NCT01523587 | LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy | completed | Phase 3 | 795 | Boehringer IngelheimINDUSTRY | 23 | Feb 15, 2019 | clinicaltrials |
| NCT00678392 | Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer | completed | Phase 3 | 723 | PfizerINDUSTRY | 22 | Jan 9, 2019 | clinicaltrials |
| NCT00876395 | Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer(BOLERO-1) | completed | Phase 3 | 719 | Novartis PharmaceuticalsINDUSTRY | 28 | Dec 19, 2018 | clinicaltrials |
| NCT00960440 | Study of CP-690,550 Versus Placebo In Rheumatoid Arthritis Patients On Background Methotrexate With Inadequate Response To Tumor Necrosis Factor (TNF) Inhibitors | completed | Phase 3 | 399 | PfizerINDUSTRY | 14 | Dec 19, 2018 | clinicaltrials |
| NCT01313689 | Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia | completed | Phase 3 | 122 | Novartis PharmaceuticalsINDUSTRY | 17 | Nov 8, 2018 | clinicaltrials |
| NCT00375674 | A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer(S-TRAC) | completed | Phase 3 | 674 | PfizerINDUSTRY | 22 | Sep 21, 2018 | clinicaltrials |
| NCT01767155 | Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer(ZoptEC) | completed | Phase 3 | 511 | AEterna ZentarisINDUSTRY | 22 | Jul 31, 2018 | clinicaltrials |
| NCT01522443 | Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer(COMET-2) | terminated | Phase 3 | 119 | ExelixisINDUSTRY | 5 | May 23, 2018 | clinicaltrials |
| NCT01571284 | Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen | completed | Phase 3 | 781 | SanofiINDUSTRY | 23 | Apr 17, 2018 | clinicaltrials |
| NCT00949650 | BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation | completed | Phase 3 | 345 | Boehringer IngelheimINDUSTRY | 25 | Apr 6, 2018 | clinicaltrials |
| NCT01605227 | Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100(COMET-1) | completed | Phase 3 | 1,028 | ExelixisINDUSTRY | 14 | Mar 14, 2018 | clinicaltrials |
| NCT02119663 | A Study of Ruxolitinib in Pancreatic Cancer Patients | terminated | Phase 3 | 86 | Incyte CorporationINDUSTRY | 14 | Feb 13, 2018 | clinicaltrials |
| NCT01002248 | Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients | terminated | Phase 3 | 135 | AEterna ZentarisINDUSTRY | 9 | Feb 9, 2018 | clinicaltrials |
| NCT01646021 | Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy | completed | Phase 3 | 280 | Janssen Research & Development, LLCINDUSTRY | 21 | Jan 19, 2018 | clinicaltrials |
| NCT00911170 | PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study | completed | Phase 3 | 847 | AmgenINDUSTRY | 17 | Dec 29, 2017 | clinicaltrials |
| NCT01307397 | A Study of Vemurafenib in Participants With Metastatic Melanoma | completed | Phase 3 | 3,219 | Hoffmann-La RocheINDUSTRY | 44 | Dec 18, 2017 | clinicaltrials |
| NCT01722487 | Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL | completed | Phase 3 | 269 | Pharmacyclics LLC.INDUSTRY | 16 | Nov 30, 2017 | clinicaltrials |
| NCT01632904 | Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study | completed | Phase 3 | 110 | Incyte CorporationINDUSTRY | 7 | Nov 14, 2017 | clinicaltrials |
| NCT01154140 | A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung(PROFILE 1014) | completed | Phase 3 | 343 | PfizerINDUSTRY | 31 | Nov 6, 2017 | clinicaltrials |
| NCT00424047 | A Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma | completed | Phase 3 | 351 | CelgeneINDUSTRY | 15 | Oct 19, 2017 | clinicaltrials |
| NCT01649856 | A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell Lymphoma | completed | Phase 3 | 572 | Hoffmann-La RocheINDUSTRY | 27 | Oct 11, 2017 | clinicaltrials |
| NCT01227889 | A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma | completed | Phase 3 | 251 | GlaxoSmithKlineINDUSTRY | 12 | Oct 4, 2017 | clinicaltrials |
| NCT01416181 | A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis(ASCEND in SPMS) | terminated | Phase 3 | 889 | BiogenINDUSTRY | 17 | Sep 11, 2017 | clinicaltrials |
| NCT00241722 | Long-Term Safety Evaluation Of Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain | completed | Phase 3 | 805 | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 17 | Aug 30, 2017 | clinicaltrials |
| NCT00431236 | A Study of the Drug Casopitant for the Prevention of Nausea Caused By Cisplatin-Based Highly Emetogenic Chemotherapy | completed | Phase 3 | 810 | GlaxoSmithKlineINDUSTRY | 22 | Aug 22, 2017 | clinicaltrials |
| NCT01360554 | ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer(ARCHER 1009) | completed | Phase 3 | 878 | PfizerINDUSTRY | 23 | May 24, 2017 | clinicaltrials |
| NCT01193244 | Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer | completed | Phase 3 | 1,560 | Millennium Pharmaceuticals, Inc.INDUSTRY | 40 | May 17, 2017 | clinicaltrials |
| NCT01874171 | Determination of Cetuximab Versus Cisplatin Early and Late Toxicity Events in HPV+ OPSCC(De-ESCALaTE) | unknown | Phase 3 | 334 | University of WarwickOTHER | 3 | May 8, 2017 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials